{"id":"W4282916823","doi":"10.1016/j.esmoop.2022.100510","title":"Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer","year":2022,"lang":"en","type":"review","venue":"ESMO Open","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Sanofi Genzyme; Genentech; Takeda Pharmaceutical Company; Janssen Pharmaceuticals; Gilead Sciences; Sanofi; Merck; Bayer; Astellas Pharma Global Development; AstraZeneca; Amgen; Pfizer; Astellas Pharma; Daiichi Sankyo Company; Clovis Oncology; Astellas Pharma US","keywords":"Enzalutamide; Prostate cancer; Hazard ratio; Medicine; Placebo; Cabazitaxel; Oncology; Internal medicine; Antiandrogen; Confidence interval; Androgen deprivation therapy; Cancer; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003657818,0.0005188705,0.002780918,0.0001586996,0.0002694324,0.00003157687,0.0006475439,0.00009033902,0.0003504906],"category_scores_gemma":[0.00006320373,0.0002378482,0.0009307759,0.000596491,0.000266326,0.0000499238,0.0001638828,0.000191918,0.000002077117],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00145878,"about_ca_system_score_gemma":0.002483711,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01012419,"about_ca_topic_score_gemma":0.003306008,"domain_scores_codex":[0.9969651,0.0003805583,0.00119645,0.0004701733,0.0006094266,0.0003783084],"domain_scores_gemma":[0.99519,0.002357527,0.001290749,0.0009603066,0.0001108888,0.00009050772],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.006556291,0.002880304,0.0003122757,0.007679029,0.007785546,0.0000156998,0.005655394,0.0001904721,0.00002305516,0.00006182689,0.0001644538,0.9686757],"study_design_scores_gemma":[0.01896894,0.01024444,0.00156559,0.005931739,0.01761987,0.00000936757,0.001855805,0.00004727893,0.002810367,0.00002102041,0.9405804,0.0003451385],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01206471,0.9651613,0.000001995222,0.0001868348,0.0004787315,0.01926909,0.002461315,0.00001179368,0.0003642448],"genre_scores_gemma":[0.008565735,0.9820628,0.0001607856,0.000005048036,0.00005967973,0.005454466,0.000657974,0.00008038909,0.002953087],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9683305,"threshold_uncertainty_score":0.9964675,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.270638878063148,"score_gpt":0.4758512421177813,"score_spread":0.2052123640546333,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}